GoingPublic Case Study on BIONCaRT
In a recent article, goingpublic.de highlights BIONCaRT, our advancements in regenerative medicine, and our innovative cell therapy approach for the treatment of cartilage defects. https://www.goingpublic.de/life-sciences/case-study-bioncart-stammzellen-fuer-die-regeneration-geschaedigter-gelenke/
BIONCaRT and Geistlich Partner in the Joint Commercialization of MesemCart and Chondro-Gide®
As part of a strategic partnership, BIONCaRT and Geistlich will combine their expertise in the field of regenerative medicine. The aim of this collaboration is the joint commercialization and distribution of a combined therapy consisting of Geistlich’s Chondro-Gide® membrane and BIONCaRT’s MesemCart cell suspension. The combination of these two technologies is expected to set new […]
MesemCart – First Patient Treated at University Hospital Dresden
An important milestone in the development of a novel, stem-cell–based therapy for the regeneration of cartilage damage has been reached: At the University Hospital Dresden, the first patient has been successfully treated under the supervision of Prof. Dr. Jörg Lützner as part of the clinical trial “MesemCart.” The Phase I/IIa study, initiated by BIONCaRT GmbH, […]
EMA Approves First-in-Human Study for MesemCart
BIONCaRT GmbH has received approval from the responsible federal authority, the Paul Ehrlich Institute, to conduct a Phase I/IIa clinical trial. The aim of the study is to investigate the safety and initial evidence of efficacy of umbilical cord tissue-derived mesenchymal stromal cells for the treatment of cartilage damage in the knee joint. The clinical […]